MS/Validation
|
Case
|
Diagnosis
|
M/F
|
Age (years)
|
Abeta
|
Tau
|
CERAD
|
PMD
|
APOE
|
---|
MS
|
1
|
CAA type-1
|
F
|
75
|
A3
|
B3
|
C0c
|
6:00
|
44
|
MS
|
2
|
CAA type-1
|
F
|
96
|
A3
|
B3
|
C0c
|
4:20
|
43
|
MS
|
3
|
CAA type-1
|
M
|
68
|
A3a
|
B1
|
C0c
|
6:05
|
44
|
MS
|
4
|
CAA type-1
|
F
|
78
|
A3
|
NA
|
C0c
|
4:20
|
44
|
MS
|
5
|
CAA type-1
|
M
|
81
|
A3
|
B3
|
C2
|
6:30
|
44
|
MS
|
6
|
CAA type-1
|
F
|
95
|
A3
|
B3
|
C2
|
4:35
|
44
|
MS
|
7
|
CAA type-1
|
M
|
80
|
A3
|
B3
|
C0c
|
5:05
|
44
|
MS
|
8
|
AD
|
F
|
82
|
A3
|
B3
|
C3
|
6:00
|
42
|
MS
|
9
|
AD
|
F
|
72
|
A3
|
B3
|
C3
|
6:30
|
44
|
MS
|
10
|
AD
|
F
|
81
|
A3
|
B3
|
C3
|
6:00
|
33
|
MS
|
11
|
AD
|
F
|
73
|
A3
|
B3
|
C3
|
5:55
|
44
|
MS
|
12
|
AD
|
M
|
84
|
A3
|
B3
|
C3
|
8:05
|
NA
|
MS
|
13
|
AD
|
F
|
87
|
A3
|
B3
|
C3
|
5:45
|
43
|
MS
|
14
|
AD
|
F
|
72
|
A3
|
B3
|
C3
|
5:55
|
23
|
MS
|
15
|
Control
|
M
|
74
|
A0
|
B0
|
C0
|
8:05
|
33
|
MS
|
16
|
Control
|
F
|
80
|
A1
|
B1
|
C0
|
6:58
|
43
|
MS
|
17
|
Control
|
M
|
82
|
A0
|
B1
|
C0
|
5:10
|
23
|
MS
|
18
|
Control
|
M
|
78
|
A0
|
B1
|
C0
|
17:40
|
33
|
MS
|
19
|
Control
|
F
|
79
|
A0
|
B1
|
C0
|
18:13
|
33
|
MS
|
20
|
Control
|
F
|
81
|
A0
|
B1
|
C0
|
4:25
|
33
|
V
|
21
|
CAA type-1
|
F
|
94
|
A3
|
B3
|
C3
|
04:30
|
43
|
V
|
22
|
CAA type-1
|
M
|
74
|
A3
|
B3
|
C3
|
03:25
|
NA
|
V
|
23
|
CAA type-1
|
F
|
87
|
A3
|
B3
|
C3
|
08:00
|
44
|
V
|
24
|
CAA type-1
|
F
|
84
|
A3
|
B3
|
C2
|
04:45
|
NA
|
V
|
25
|
CAA type-1
|
M
|
88
|
A3
|
B3
|
C3
|
03:55
|
NA
|
V
|
26
|
CAA type-1
|
M
|
75
|
A3
|
B3
|
C0
|
03:15
|
NA
|
V
|
27
|
AD
|
M
|
64
|
A3
|
B3
|
C3
|
07:30
|
33
|
V
|
28
|
AD
|
F
|
81
|
A3
|
B3
|
C3
|
05:15
|
43
|
V
|
29
|
AD
|
F
|
90
|
A3
|
B3
|
C3
|
04:45
|
33
|
V
|
30
|
AD
|
M
|
65
|
A3
|
B3
|
C3
|
06:00
|
43
|
V
|
31
|
AD
|
F
|
73
|
A3
|
B3
|
C3
|
NA
|
NA
|
V
|
32
|
AD
|
F
|
90
|
A3
|
B3
|
C3
|
03:55
|
32
|
V
|
33
|
AD
|
M
|
88
|
A3
|
B3
|
C3
|
04:40
|
43
|
V
|
34
|
AD
|
M
|
74
|
A3
|
B3
|
C3
|
05:10
|
NA
|
V
|
35
|
Control
|
M
|
73
|
A0
|
B0
|
C0
|
24:45
|
33
|
V
|
36
|
Control
|
M
|
71
|
A0
|
B1
|
C0
|
07:40
|
33
|
V
|
37
|
Control
|
F
|
82
|
A0
|
B1
|
C0
|
07:00
|
33
|
V
|
38
|
Control
|
M
|
56
|
A0
|
B0
|
C0
|
09:15
|
43
|
V
|
39
|
Control
|
M
|
62
|
A0
|
B1
|
C0
|
07:20
|
33
|
V
|
40
|
Control
|
M
|
76
|
A0
|
B0
|
C0
|
06:45
|
33
|
V
|
41
|
Control
|
M
|
93
|
A0
|
B1
|
C0
|
05:05
|
33
|
V
|
42
|
Control
|
F
|
60
|
A0
|
B0
|
C0
|
08:10
|
32
|
V
|
43
|
Cotton wool
|
M
|
72
|
A3
|
B3
|
C0c
|
05:15
|
43
|
V
|
44
|
Prp-CAA
|
F
|
57
|
A0
|
B0b
|
C0
|
24:00
|
NA
|
V
|
45
|
CADASIL
|
M
|
73
|
A0
|
B0
|
C0
|
31:45
|
NA
|
V
|
46
|
CARASAL
|
F
|
55
|
A1
|
B1
|
C0
|
04:00
|
NA
|
V
|
47
|
Hyper tension related SVD
|
F
|
92
|
A1
|
B2
|
C0
|
07:25
|
NA
|
- Alzheimer’s disease: AD, cerebral amyloid angiopathy: CAA, M: male, F: female, post mortem delay: PMD, not available/not applicable: NA, used for mass spectrometry analysis: MS, used for validation: V. (aAβ only present as dysphoric CAA) (bFocal tau accumulation around blood vessels with prp-amyloid deposits) (conly dyshoric angiopathy in gallyas staining)